Araştırma Makalesi

Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus

Cilt: 18 Sayı: 1 28 Nisan 2021
PDF İndir
EN TR

Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus

Abstract

Background: To evaluate the safety and efficacy of corneal crosslinking (CXL) treatment in children with keratoconus. Materials and Methods:A total of 45 eyes of 34 children with progressive keratoconus were included in this study. CXL was performed according to the conventional method. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal topography values, and endothelial cell density (ECD) were evaluated at baseline and 24-month follow-up. Results:The mean age of the patients was 14.6 ± 3.5 years. The mean spherical equivalent readings were statistically significantly decreased at 24 months (p=0.016). There was a significant improvement in the mean UDVA and CDVA at 24 months (p=0.002, p=0.006, respectively). The mean K1 and K2 were statistically significantly reduced at 24 months postoperatively (p=0.004, p=0.006, respectively). There was no significant alteration in ECD at any follow-up examination. No significant sight-threatening complications were observed. Conclusions: The CXL procedure seem to be safe and effective in stabilizing keratoconus progression in children within a follow-up of 24 months.

Keywords

Kaynakça

  1. 1.Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998; 42(4):297-319.
  2. 2.El-Khoury S, Abdelmassih Y, Hamade A, Slim E, Cherfan CG, Chelala E, et al. Pediatric keratoconus in a tertiary referral center: incidence, presentation, risk factors, and treatment. J Refract Surg. 2016; 32(8):534-41.
  3. 3.Sabti S, Tappeiner C, Frueh BE. Corneal cross-linking in a 4-year-old child with keratoconus and Down syndrome. Cornea. 2015; 34(9):1157-60.
  4. 4.Vinciguerra P, Albe E, Frueh BE, Trazza S, Epstein D. Two-year corneal cross-linking results in patients younger than 18 years with documented progressive keratoconus. Am J Ophthalmol. 2012; 154(3):520-6.
  5. 5.Leoni-Mesplie S, Mortemousque B, Touboul D, Malet F, Praud D, Mesplie N, et al. Scalability and severity of keratoconus in children. Am J Ophthalmol. 2012; 154(1):56-62.
  6. 6.Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the teratment of keratoconus. Am J Ophthalmol. 2003; 135(5):620-7.
  7. 7.O’Brart DP, Kwong TQ, Patel P, McDonald RJ, O’Brart NA. Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconus. Br J Ophthalmol.2013; 97(4):433-7.
  8. 8.Ghanem RC, Santhiago MR, Berti T, Netto MV, Ghanem VC. Topographic, corneal wavefront and refractive outcomes 2 years after collgen crosslinking for progressive keratoconus. Cornea. 2014; 33(1):43-51.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

28 Nisan 2021

Gönderilme Tarihi

22 Şubat 2021

Kabul Tarihi

15 Mart 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 18 Sayı: 1

Kaynak Göster

Vancouver
1.Deniz Özarslan Özcan, Sait Coşkun Özcan. Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus. Harran Üniversitesi Tıp Fakültesi Dergisi. 01 Nisan 2021;18(1):145-8. doi:10.35440/hutfd.885032

Bu dergide yayınlanan makaleler Creative Commons Atıf-GayriTicari-AynıLisanslaPaylaş 4.0 (CC-BY-NC-SA 4.0) Uluslararası Lisansı ile lisanslanmıştır.